Skip to Main Content

Paper Details

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Blood Cancer Discov
14
2021
Avadomide, B, B-cell malignancies, CC-122, CRBN, CRL4CRBN, E3 ubiquitin ligase, FGFR1, FLT3, IKZF1, IKZF3, MYM domain, N, Thalidomide, ZMYM2, ZMYM2 fusion oncoproteins, ZMYM2 fusion proteins, ZNF198, avadomide, drug-responsive element, hematologic malignancies, patients, zinc
Author NameAffiliation
Jessica A GasserBroad Institute of MIT and Harvard
Jessica A GasserDana-Farber Cancer Institute
Pierre M Jean BeltranBroad Institute of MIT and Harvard
Thomas ClaytonCelgene/Bristol-Myers Squibb Corporation
Steven A CarrBroad Institute of MIT and Harvard
Steven A CarrBroad Institute of MIT and Harvard
Benjamin L EbertBroad Institute of MIT and Harvard
Benjamin L EbertDana-Farber Cancer Institute
Benjamin L EbertHoward Hughes Medical Institute, Dana-Farber Cancer Institute
  • 1 - 9

Datasets

Release 1.2